Page 138 - 《中国药房》2023年5期

2022，61（6）：789-817. Does haemodialysis significantly affect serum linezolid
[28] PEA F，VIALE P，COJUTTI P，et al. Therapeutic drug concentrations in critically ill patients with renal failure?
monitoring may improve safety outcomes of long-term A pilot investigation[J]. Nephrol Dial Transplant，2006，21
treatment with linezolid in adult patients[J]. J Antimicrob （5）：1402-1406.
Chemother，2012，67（8）：2034-2042. [42] CHENG C N，LIN S W，WU C C. Early linezolid-
[29] ZOLLER M，MAIER B，HORNUSS C，et al. Variability associated lactic acidosis in a patient with Child’s class C
of linezolid concentrations after standard dosing in criti‐ liver cirrhosis and end stage renal disease[J]. J Infect Che‐
cally ill patients：a prospective observational study[J]. Crit mother，2018，24（10）：841-844.
Care，2014，18（4）：R148. [43] ZHANG S H，ZHU Z Y，CHEN Z，et al. Population phar‐
[30] 曹伟，卢志品，余剑华. 利奈唑胺是否需要血药浓度监测 macokinetics and dosage optimization of linezolid in pa‐
[J]. 中国新药与临床杂志，2016，35（10）：690-694. tients with liver dysfunction[J]. Antimicrob Agents Che‐
[31] RAO G G，KONICKI R，CATTANEO D，et al. Therapeu‐ mother，2020，64（6）：e00133-e00120.
tic drug monitoring can improve linezolid dosing regi‐ [44] XIE F F，MANTZARLIS K，MALLIOTAKIS P，et al.
mens in current clinical practice：a review of linezolid Pharmacokinetic evaluation of linezolid administered in‐
pharmacokinetics and pharmacodynamics[J]. Ther Drug travenously in obese patients with pneumonia[J]. J Antimi‐
Monit，2020，42（1）：83-92. crob Chemother，2019，74（3）：667-674.
[32] LI L，LI X，XIA Y Z，et al. Recommendation of antimicro‐ [45] 张雷，白楠，刘又宁，等. 利奈唑胺在中国人的群体药代
bial dosing optimization during continuous renal replace‐ 动力学特点[J]. 中华结核和呼吸杂志，2016，39（12）：
ment therapy[J]. Front Pharmacol，2020，11：786. 924-928.
[33] KÜHN D，METZ C，SEILER F，et al. Antibiotic therapeu‐ [46] MIYAMOTO T，TOMOYASU T，MIYAJI K. Successful
tic drug monitoring in intensive care patients treated with treatment of pediatric endocarditis and pericarditis due to
different modalities of extracorporeal membrane oxygena- MRSA with linezolid[J]. Jpn J Antibiot，2011，64（2）：
tion （ECMO） and renal replacement therapy：a prospec‐ 109-112.
tive，observational single-center study[J]. Crit Care，2020， [47] 李思婵，徐华，叶琦，等. 利奈唑胺成人药动学数据在儿
24（1）：664. 童群体中的外推及暴露量-疗效关系研究[J]. 中国医院
[34] FAYAD A I，BUAMSCHA D G，CIAPPONI A. Timing of 药学杂志，2019，39（7）：720-726.
kidney replacement therapy initiation for acute kidney injury [48] LI S C，YE Q，XU H，et al. Population pharmacokinetics
[J]. Cochrane Database Syst Rev，2022，11（11）：CD010612. and dosing optimization of linezolid in pediatric patients
[35] BARRASA H，SORALUCE A，ISLA A，et al. Pharmaco‐ [J]. Antimicrob Agents Chemother，2019，63（4）：e02387-
kinetics of linezolid in critically ill patients on continuous e02318.
renal replacement therapy：influence of residual renal [49] JELLIFFE R W. Some comments and suggestions con‐
function on PK/PD target attainment[J]. J Crit Care，2019， cerning population pharmacokinetic modeling，especially
50：69-76. of digoxin，and its relation to clinical therapy[J]. Ther
[36] CORCIONE S，D’AVOLIO A，ALLEGRA S，et al. Phar‐ Drug Monit，2012，34（4）：368-377.
macokinetics of linezolid in critically ill patients：impact [50] 张弨，翟所迪. 群体药动学在治疗药物监测中的应用[J].
of continuous venovenous haemofiltration[J]. Int J Antimi‐ 临床药物治疗杂志，2006，4（1）：45-50.
crob Agents，2017，49（6）：784-785. [51] SANTIMALEEWORAGUN W，CHANGPRADUB D，
[37] IDE T，TAKESUE Y，IKAWA K，et al. Population phar‐ HEMAPANPAIROA J，et al. Optimization of linezolid
macokinetics/pharmacodynamics of linezolid in sepsis pa‐ dosing regimens for treatment of vancomycin-resistant en‐
tients with and without continuous renal replacement terococci infection[J]. Infect Chemother，2021，53（3）：
therapy[J]. Int J Antimicrob Agents，2018，51（5）：745-751. 503-511.
[38] WICHA S G，MAIR A，CHIRIAC U，et al. Population [52] BLACKMAN A L，JARUGULA P，NICOLAU D P，et al.
pharmacokinetics and toxicodynamics of continuously in‐ Evaluation of linezolid pharmacokinetics in critically ill
fused linezolid in critically ill patients[J]. Int J Antimicrob obese patients with severe skin and soft tissue infections
Agents，2022，59（5）：106572. [J]. Antimicrob Agents Chemother，2021，65（2）：e01619-
[39] LE FLOCH R，ARNOULD J F，VINSONNEAU C，et al. e01620.
Pharmacocinétique du linézolide chez des patients souffrant [53] ALGHAMDI W A，AL-SHAER M H，AN G H，et al.
de brûlures sévères[J]. Pathol Biol，2010，58（2）：e27-e31. Population pharmacokinetics of linezolid in tuberculosis
[40] TSUJI Y，YUKAWA E，HIRAKI Y，et al. Population phar‐ patients：dosing regimen simulation and target attainment
macokinetic analysis of linezolid in low body weight pa‐ analysis[J]. Antimicrob Agents Chemother，2020，64（10）：
tients with renal dysfunction[J]. J Clin Pharmacol，2013， e01174-e01120.
53（9）：967-973. （收稿日期：2022-06-29 修回日期：2023-01-03）
[41] FIACCADORI E，MAGGIORE U，ROTELLI C，et al. （编辑：唐晓莲）

· 640 · China Pharmacy 2023 Vol. 34 No. 5 中国药房 2023年第34卷第5期